Consistent with the in vitro expression evidence, ribosomal dysfunction enhanced the survival-linked ERK1/2 signals, downregulating expression of the anticancer-related IGFBP3 in cancer cells under chemotherapeutic action (Fig. 6b). Here, IGFBP3 is linked to cancer.